Yesterday’s court decision in AstraZeneca’s 340B contract pharmacy lawsuit made the final score 6-0 in favor of drug manufacturers in their fight with the federal government over the legality of its May 17, 2021, letters telling Astra, Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics that their actions have resulted in overcharges and are in direct violation of the 340B statute.
AstraZeneca Court Ruling Means All Six of HRSA’s 340B Original Contract Pharmacy Violation Letters are Dead
